MTAP抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P02831(MTAP Antibody) at dilution 1/70. (Original magnification: ×200)    

  
  

Methylthioadenosine phosphorylase (MTAP) is a key enzyme in the methionine salvage pathway, catalyzing the conversion of methylthioadenosine (MTA) to adenine and 5-methylthioribose-1-phosphate. This metabolic pathway is critical for recycling methionine and adenine, particularly in conditions of limited nutrient availability. The MTAP gene is located on chromosome 9p21.3. a genomic region frequently deleted in various cancers, including glioblastoma, pancreatic cancer, and melanoma. Loss of MTAP expression is often linked to co-deletion with the tumor suppressor gene CDKN2A, making MTAP deficiency a potential biomarker for 9p21 loss and a therapeutic target.

MTAP antibodies are widely used in research to detect MTAP protein levels via techniques like immunohistochemistry, Western blotting, or flow cytometry. These antibodies help assess MTAP status in tumors, which has gained interest due to its implications in precision medicine. MTAP-deficient cancers exhibit metabolic vulnerabilities, such as heightened sensitivity to inhibitors of de novo purine synthesis (e.g., L-alanosine) or methionine deprivation therapies. Additionally, MTAP loss may influence the tumor microenvironment by accumulating MTA, which has immunomodulatory effects. Recent studies explore MTAP’s role in predicting response to therapies targeting PRMT5 or MAT2A, offering novel strategies for treating MTAP-deficient malignancies. Overall, MTAP antibodies serve as essential tools for understanding cancer metabolism and developing targeted therapies.